Journal of Bioequivalence & Bioavailability

Current Issue

Biowaivers and Biosimilars, 2021

Perspective

Bioequivalence Significance and Its Utilizes

• Macroni Laco

Volume 13, Issue 3, 2021

Mini Review

Sources of Omega-3 Fatty Acids

• Stephan Prabu

Volume 13, Issue 5, 2021

Mini Review

Biomarkers as a Diagnostic Tool in Cancer: A Boon or a Bane?

• Priyanka Varma*

Research Article

An Open-label, Randomized, Single-dose, Crossover Study in Healthy Adult Volunteers to Evaluate Pharmacokinetic Interactions and Tolerability of a Fixed-dose Combination with Rosuvastatin and Ezetimibe

• Jorge González-Canudas*, Luis J.García-Aguirre, Araceli G. Medina-Nolasco, Yulia Romero-Antonio and Laura A. Lugo Sánchez

Research Article

Single-Dose, Open-Label, One-Way Pharmacokinetic Studies In The Mexican Population To Evaluate The Bioavailability And Food Effect On The Pharmacokinetics Of 30-mg Extended-Release Nifedipine Tablets

• Alberto Martínez-Muñoz, Karen Nathalie Geraldo-Bastida, Alondra Nataly Lobatos-Buenrostro, Juan Luis Gutiérrez-Velázquez, Carlos Joel Salas-Montantes, Héctor Manuel González-Martínez, Araceli Guadalupe Medina-Nolasco, Porfirio de la Cruz-Cruz, Sandra Lara-Figueroa, Ricardo Zamora-Ramírez, José Luis Rubio-Santiago

Mini Review

New Biomarkers for the Prevention and Treatment of Diabetes

• Akira Matsumori*

Short Communication

Compliance to WHO’S Strategic Preparedness and Response Plan 2019 (n-CoV): Success Story of Department of Indian Medicine, Tamilnadu

• Ganesh S, Parthiban P, Kanakavalli K, Sathiyarajeswaran P and Shree Devi MS*

Recent advancements in bioequivalence studies, 2021

Research

Effect of Polyethylene Glycol on Growth of Escherichia coli DH5α and Bacillus subtilis NRS-762

• Wenfa NG*

Research

Drastic Decline in Optical Density during Stationary Phase Meant that Bacillus subtilis NRS-762 is not Suitable as Model Organism in Microbial Survivability Studies

• Wenfa NG*

Editorial

A brief Note on Bioavailability and Its Significance

• Jessica Statin*

Editorial

A Brief Note on Various Drug Delivery Systems

• Jessica Statin*

Commentary

An Overview on Bioavailability’s and Bioequivalence

• Bill Brashier*

Volume 14, Issue 3, 2022

Research Article

Levetiracetam Coated Tablet: A Randomized, Single-Dose, Two-Sequence, TwoPeriod, Crossover Study to Assess the Bioequivalence between Two Formulations

• Marcelo Gomes Davanço*, Jessica Meulman, Fernando Costa, Leonardo de Souza Teixeira, Iram Moreira Mundim, Karini Bruno Bellorio, Carina Pimentel, Itapema Alves and Celso Francisco Pimentel Vespasiano

DOI: 10.35248/0975-0851.22.14.458

Commentary

Efficacy and Safety of Trimetazidine Therapy in Patients with Coronary Artery Disease

• Kim Jean*

DOI: 10.35248/0975-0851.22.14.459

Opinion Article

Management of Urinary Catheratisation Process and Types of Urinary Catheters

• Pencheva Lennon*

DOI: 10.35248/0975-0851.22.14.460

Perspective

The Potential Use of Simvastatin for Cholesterol and Triglycerides Disorders

• Chung Rae*

DOI: 10.35248/0975-0851.22.14.461

Commentry

Acarbose Medication for Type 2 Diabetes Mellitus Treatment

• Roan Yang*

DOI: 10.35248/0975-0851.22.14.462

Volume 17, Issue 3, 2025

Commentary

Factors Influencing Oral Drug Absorption and Bioavailability

• Peng Miao*

DOI: 10.35248/0975-0851.25.17.633

Commentary

The Role of Pharmacodynamics in Therapeutic Effectiveness

• Annette Gaiser*

DOI: 10.35248/0975-0851.25.17.634

Commentary

Advances in the Study of Drug Metabolic Processes

• Dominique Lunter*

DOI: 10.35248/0975-0851.25.17.635

Commentary

The Importance of Clinical Pharmacology in Modern Medicine

• Everton Albigo*

DOI: 10.35248/0975-0851.25.17.636

Perspective

The Role of Generic Drugs in Modern Healthcare

• Maciej Winiarski*

DOI: 10.35248/0975-0851.25.17.637

Perspective

The Science and Strategy of Pharmaceutical Formulation Development

• Xiuxin Zhong*

DOI: 10.35248/0975-0851.25.17.638

Perspective

Regulatory Guidelines in Drug Development and Approval

• Yvonne Schnaars*

DOI: 10.35248/0975-0851.25.17.639

Opinion Article

The Role of Drug Interactions in Bioavailability and Therapeutic Outcomes

• Chunyan Gan*

DOI: 10.35248/0975-0851.25.17.640

Opinion Article

Advances in Understanding Drug Biotransformation and Bioequivalence

• Anne Manson*

DOI: 10.35248/0975-0851.25.17.641

Opinion

The Scientific and Regulatory Basis of Therapeutic Equivalence

• Humberto Gomes*

DOI: 10.35248/0975-0851.25.17.642

Volume 17, Issue 4, 2025

Short Communication

Bioequivalence Principles and Implications in Drug Development

• Rang Malouh*

DOI: 10.35248/0975-0851.25.17.643

Commentary

Biopharmaceutics in Drug Development and Therapeutic Optimization

• Jue Marianna*

DOI: 10.35248/0975-0851.25.17.644

Commentary

Bioavailability and Its Role in Effective Drug Development

• Sylvia Wen*

DOI: 10.35248/0975-0851.25.17.645

Commentary

Clinical Pharmacology A Pillar for Bioequivalence and Bioavailability Studies

• Diewerke Li*

DOI: 10.35248/0975-0851.25.17.646

Perspective

Pharmacokinetic Comparison A Critical Tool in Assessing Bioavailability and Bioequivalence

• Carla Zhang*

DOI: 10.35248/0975-0851.25.17.647

Perspective

Comparative Study, Drug Metabolism and Its Impact on Pharmacokinetics and Therapeutic Outcomes

• Yilei Wang*

DOI: 10.35248/0975-0851.25.17.648

Perspective

Therapeutic Equivalence Cornerstone for Ensuring Safe and Effective Generic Drug Substitution

• Cheng Karalliedde*

DOI: 10.35248/0975-0851.25.17.649

Opinion Article

Advancing Clinical Equivalence Assessment in Generic Drug Development

• Mario Miller*

DOI: 10.35248/0975-0851.25.17.650

Opinion Article

Role of Drug Metabolism in Determining Pharmacokinetics and Therapeutic Outcomes

• Ben Fouad*

DOI: 10.35248/0975-0851.25.17.651

Opinion Article

Pharmacodynamics Role in Drug Efficacy, Safety, and Implications for Bioequivalence Studies

• Chunhui Divina*

DOI: 10.35248/0975-0851.25.17.652

Volume 17, Issue 5, 2025

Short Communication

Innovations and Impact of Clinical Cancer Trials in Modern Oncology

• Thomas Berger*

DOI: 10.35248/0975-0851.25.17.662

Commentary

Evaluating Bioequivalence in Antipsychotic Medications and Its Clinical Relevance

• Ananya Rao*

DOI: 10.35248/0975-0851.25.17.653

Commentary

Bioequivalence Assessment of Antipsychotic Drugs in Modern Psychiatric Practice

• Michael Thompson*

DOI: 10.35248/0975-0851.25.17.654

Commentary

Biosimilars as a Sustainable Pathway for Advancing Modern Therapeutics

• Kavita Menon*

DOI: 10.35248/0975-0851.25.17.655

Perspective

The Evolving Role of Biosimilars in Enhancing Global Healthcare Access

• Alejandro Castillo*

DOI: 10.35248/0975-0851.25.17.656

Perspective

Food and Drug Administration Bioequivalence Framework and Its Impact on Generic Medicines

• Robert Anderson*

DOI: 10.35248/0975-0851.25.17.657

Perspective

Economic Participation and Ethical Balance in Paid Clinical Trials

• Vikram Sen*

DOI: 10.35248/0975-0851.25.17.658

Opinion Article

Financial Incentives and Social Responsibility in Paid Clinical Research

• Michael Turner*

DOI: 10.35248/0975-0851.25.17.659

Opinion Article

Regulatory Perspectives on European Bioequivalence Studies

• Sophie Lambert*

DOI: 10.35248/0975-0851.25.17.660

Opinion Article

Scientific and Public Health Implications of Bioequivalence in Europe

• Helena Fischer*

DOI: 10.35248/0975-0851.25.17.661

Volume 18, Issue 1, 2026

Review Article

Hepatic Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation in Pediatric Patients: A Review of Assessment for Liver Stiffness Measurement by Elastography along with Defibrotide Efficacy

• Kazumi Fujioka*

DOI: 10.35248/0975-0851.26.18.673

Commentary

Role of Drug Absorption in Bioequivalence Studies

• Laura Mezler*

DOI: 10.35248/0975-0851.26.18.674

Commentary

Principles of Biopharmaceutics in Pharmaceutical Sciences

• Qinyuan Lukacova*

DOI: 10.35248/0975-0851.26.18.675

Commentary

Emerging Trends in Biosimilars and Biopharmaceuticals

• Muataz Amare*

DOI: 10.35248/0975-0851.26.18.676

Perspective

Impact of Population Pharmacokinetics on Therapeutic Outcomes

• Tomita Yoshida*

DOI: 10.35248/0975-0851.26.18.677

Perspective

Advances in Drug Permeability and Formulation Strategies

• Keiko Nagato*

DOI: 10.35248/0975-0851.26.18.678

Perspective

Therapeutic Equivalence Ensuring Interchangeability of Drug Products

• Panithi Chen*

DOI: 10.35248/0975-0851.26.18.679

Opinion Article

Liposomes in Pharmaceutical and Clinical Applications

• Petra Siven*

DOI: 10.35248/0975-0851.26.18.680

Opinion Article

Role of First Pass Metabolism in Drug Bioavailability

• Natalie Clark*

DOI: 10.35248/0975-0851.26.18.681

Opinion Article

Role of Pharmacokinetic Modelling in Drug Disposition Studies

• Ryo Okada*

DOI: 10.35248/0975-0851.26.18.682

Volume 18, Issue 2, 2026

Short Communication

Smart Adaptive Modeling of Biological Timing Effects in Drug Absorption

• Ethan Caldwell*

DOI: 10.35248/0975-0851.26.18.683

Opinion Article

Genomic Nutrition Interactions Regulating Therapeutic Absorption Pathways

• Sofia Martinez*

DOI: 10.35248/0975-0851.26.18.684

Opinion Article

Sex Dependent Pharmacokinetic Variability in Therapeutic Equivalence Evaluation

• Lucas Reinhardt*

DOI: 10.35248/0975-0851.26.18.685

Opinion Article

Sensor-Driven Therapeutic Monitoring and Systemic Exposure Analytics

• Amelie Laurent*

DOI: 10.35248/0975-0851.26.18.686

Perspective

Computational Similarity Metrics Transforming Solid Oral Performance Prediction

• Olivia Bennett*

DOI: 10.35248/0975-0851.26.18.687

Perspective

Vesicular Transport Optimization Governing Oral Systemic Uptake Enhancement

• David Kim*

DOI: 10.35248/0975-0851.26.18.688

Perspective

Quantum Confinement Strategies Enhancing Precision Pharmacokinetics

• Sophie Dubois*

DOI: 10.35248/0975-0851.26.18.689

Commentary

Individualized Dissolution Mapping for Predictive Therapeutic Performance

• Benjamin Wright*

DOI: 10.35248/0975-0851.26.18.690

Commentary

Additive Manufacturing Approaches Influencing Therapeutic Release Dynamics

• Thomas Weber*

DOI: 10.35248/0975-0851.26.18.691

Commentry

Adaptive Computational Architectures for Predicting Systemic Drug Exposure

• Alexander Petrov*

DOI: 10.35248/0975-0851.26.18.692

Volume 17, Issue 6, 2025

Research Article

Comparative Bioavailability Study of Ultra Q 300 and COQ300 Coenzyme Q10 in Healthy Adults.

• SM Rahman, Honey Qureshi, Poorneshwar Sawant, Sunil Kulkarni, Ravindra Mote* and Parikshit Champanerkar

DOI: 10.35248/0975-0851.25.17.671

Research Article

Pharmacokinetic Bridging Study To Support The Use Of Nemolizumab Prefilled Pen For The Treatment Of Atopic Dermatitis And Prurigo Nodularis

• Luca Loprete*, Jabbar Lopez Z, Piketty C, Rasmussen S, Silverberg J, Stander S, Duval V, Machu JL, Ulianov L and Wagner N

DOI: 10.35248/0975-0851.25.17.670

Commentary

Transforming Drug Effectiveness Through Modern Bioavailability Strategies

• Elena Martinez*

DOI: 10.35248/0975-0851.25.17.663

Commentary

The Role of Bioequivalence in Expanding Access to Cancer Medicines

• Arjun Rao*

DOI: 10.35248/0975-0851.25.17.664

Commentary

Understanding Compensation and Ethics in Clinical Trial Participation

• Sofia Lindstrom*

DOI: 10.35248/0975-0851.25.17.665

Perspective

Ensuring Consistent Drug Evaluation Through Bioequivalence Protocols

• Michael Osei*

DOI: 10.35248/0975-0851.25.17.666

Perspective

Exploring Experimental Drug Trials in the Pathway to Medical Innovation

• Lucas Ferreira*

DOI: 10.35248/0975-0851.25.17.667

Perspective

Evaluating Bioequivalence in Antipsychotic Medications for Consistent Patient Care

• Hana Kim*

DOI: 10.35248/0975-0851.25.17.668

Opinion Article

Advancements and Outcomes in Clinical Drug Trials: Bridging Research and Patient Care

• Ayesha Rahman*

DOI: 10.35248/0975-0851.25.17.669

Review Article

Giant Cell Arteritis after COVID-19 Vaccination along with Immuno-Pathogenesis of this Entity

• Kazumi Fujioka*

DOI: 10.35248/0975-0851.23.15.672